Tetramer-guided Analysis of TCR Beta-chain Usage Reveals a Large Repertoire of Melan-A-specific CD8+ T Cells in Melanoma Patients
Overview
Authors
Affiliations
The assessment of the TCR repertoire expressed by tumor-specific CD8+ T lymphocytes has been hampered to date by the difficulty of targeting the analysis to lymphocytes directed against a single epitope. In the present study we have used fluorescent A2/Melan-A tetramers in conjunction with anti-CD8 and anti-TCR beta-chain variable (BV) mAbs to analyze by flow cytometry the BV segment usage by Melan-A-specific CD8+ T cells in tumor-infiltrated lymph nodes (TILN) and tumor-infiltrating lymphocytes (TIL) from A2 melanoma patients. Analysis of TILN populations revealed small proportions of A2/Melan-A tetramer+ cells expressing many different BV together with over-representation of A2/Melan-A tetramer+ cells expressing certain BVs. The BV usage by A2/Melan-A tetramer+ lymphocytes in TIL was more restricted than that in TILN. Moreover, the predominant BV segments were quite distinct in populations derived from different patients. A2/Melan-A tetramer+ cells expressing the dominant BVs found in TILN could also be found in the corresponding peptide-stimulated autologous PBMC, although A2/Melan-A tetramer+ lymphocytes expressing additional BVs were also identified. Together, these results suggest that a large and diverse repertoire of Melan-A-specific T cells using different BV TCR segments is available in A2 melanoma patients.
Arakawa A, Vollmer S, Tietze J, Galinski A, Heppt M, Burdek M Front Immunol. 2019; 10:1336.
PMID: 31275310 PMC: 6591437. DOI: 10.3389/fimmu.2019.01336.
Nakatsugawa M, Rahman M, Yamashita Y, Ochi T, Wnuk P, Tanaka S Sci Rep. 2016; 6:23821.
PMID: 27030642 PMC: 4814874. DOI: 10.1038/srep23821.
Specific roles of each TCR hemichain in generating functional chain-centric TCR.
Nakatsugawa M, Yamashita Y, Ochi T, Tanaka S, Chamoto K, Guo T J Immunol. 2015; 194(7):3487-500.
PMID: 25710913 PMC: 4369446. DOI: 10.4049/jimmunol.1401717.
Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes.
Weder P, Schumacher T, Spits H, Luiten R Results Immunol. 2013; 2:88-96.
PMID: 24371571 PMC: 3862383. DOI: 10.1016/j.rinim.2012.04.001.
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.
Wieers G, Demotte N, Godelaine D, van der Bruggen P Cancers (Basel). 2013; 3(3):2904-54.
PMID: 24212939 PMC: 3759179. DOI: 10.3390/cancers3032904.